Alterity Therapeutics (ATHE) Short Interest Ratio & Short Volume $5.40 +0.19 (+3.65%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$5.35 -0.05 (-0.93%) As of 08/5/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Alterity Therapeutics Short Interest DataAlterity Therapeutics (ATHE) has a short interest of 155,100 shares, representing 1.06% of the float (the number of shares available for trading by the public). This marks a 20.33% increase in short interest from the previous month. The short interest ratio (days to cover) is 2.4, indicating that it would take 2.4 days of the average trading volume of 208,597 shares to cover all short positions.Current Short Interest155,100 sharesPrevious Short Interest128,900 sharesChange Vs. Previous Month+20.33%Dollar Volume Sold Short$693.30 thousandShort Interest Ratio2.4 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares8,870,000 sharesFloat Size14,630,000 sharesShort Percent of Float1.06%Today's Trading Volume38,776 sharesAverage Trading Volume208,597 sharesToday's Volume Vs. Average19% Short Selling Alterity Therapeutics? Sign up to receive the latest short interest report for Alterity Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartATHE Short Interest Over TimeATHE Days to Cover Over TimeATHE Percentage of Float Shorted Over Time Alterity Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/2025155,100 shares $693.30 thousand +20.3%1.1%2.4 $4.47 6/30/2025128,900 shares $527.20 thousand +10.4%0.9%3 $4.09 6/15/2025116,800 shares $513.92 thousand -8.6%0.8%2.8 $4.40 5/31/2025127,800 shares $569.99 thousand +2.9%0.9%3.2 $4.46 5/15/2025124,200 shares $470.72 thousand +147.9%0.9%2.9 $3.79 4/30/202550,100 shares $173.35 thousand -11.8%0.4%1.1 $3.46 4/15/202556,800 shares $187.44 thousand +32.7%0.4%0.1 $3.30 3/31/202542,800 shares $145.13 thousand -21.6%0.3%0.1 $3.39 3/15/202554,600 shares $215.12 thousand -46.4%0.5%0.1 $3.94 2/28/2025101,800 shares $403.54 thousand -36.2%1.0%0.2 $3.96 Get the Latest News and Ratings for ATHE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/2025159,500 shares $704.99 thousand -71.2%1.5%0.4 $4.42 1/31/2025553,500 shares $2.66 million +556.6%6.4%1.2 $4.80 1/15/202584,300 shares $279.03 thousand -49.6%1.0%1.3 $3.31 12/31/2024167,300 shares $553.76 thousand +12.6%2.0%2.6 $3.31 12/15/2024148,600 shares $356.64 thousand +7,330.0%1.8%3.2 $2.40 11/30/20242,000 shares $2.82 thousand -46.0%0.0%0 $1.41 11/15/20243,700 shares $4.09 thousand +2.8%0.0%0.3 $1.11 10/31/20243,600 shares $4.14 thousand -41.9%0.0%0.3 $1.15 10/15/20246,200 shares $7.81 thousand -36.1%0.1%0.4 $1.26 9/30/20249,700 shares $12.73 thousand -22.4%0.1%0.3 $1.31 9/15/202412,500 shares $15.75 thousand -40.5%0.2%0.4 $1.26 8/31/202421,000 shares $31.29 thousand -8.7%0.3%0.6 $1.49 8/15/202423,000 shares $31.74 thousand -18.2%0.3%0.7 $1.38 7/31/202428,100 shares $44.96 thousand +57.0%0.3%0.8 $1.60 7/15/202417,900 shares $35.98 thousand +33.6%0.2%0.4 $2.01 6/30/202413,400 shares $24.25 thousand -40.4%0.2%0.2 $1.81 6/15/202422,500 shares $41.85 thousand +8.2%0.3%0.3 $1.86 5/31/202420,800 shares $38.90 thousand -40.6%0.3%0.3 $1.87 5/15/202435,000 shares $71.40 thousand -59.3%0.4%0.4 $2.04 4/30/202485,900 shares $179.96 thousand -4.9%1.0%1.1 $2.10 4/15/202490,300 shares $221.24 thousand +290.9%1.1%1.1 $2.45 3/31/202423,100 shares $47.82 thousand -12.5%0.3%0.6 $2.07 3/15/202426,400 shares $46.46 thousand +47.5%0.3%0.6 $1.76 2/29/202417,900 shares $33.47 thousand -52.7%0.2%0.3 $1.87 2/15/202437,800 shares $76.36 thousand +25.6%0.5%0.1 $2.02 1/31/202430,100 shares $63.51 thousand +85.8%N/A0 $2.11 1/15/202416,200 shares $30.78 thousand -77.0%0.3%0 $1.90 12/31/202370,500 shares $175.55 thousand +22.8%1.2%0.1 $2.49 12/15/202357,400 shares $173.92 thousand +12.6%1.3%0.1 $3.03 11/30/202351,000 shares $92.31 thousand +684.6%1.2%0.1 $1.81The End of Elon Musk…? (Ad)The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.Click here to see why the "End of Elon" crowd is about to be wrong again. 11/15/20236,500 shares $15.93 thousand -11.0%0.2%1.2 $2.45 10/31/20237,300 shares $17.02 thousand -32.4%0.2%2.6 $2.33 10/15/202310,800 shares $26.24 thousand -12.9%0.3%3.4 $2.43 9/30/202312,400 shares $30.75 thousand -13.3%0.3%3.2 $2.48 9/15/202314,300 shares $37.18 thousand -14.4%0.4%3.6 $2.60 8/31/202316,700 shares $45.26 thousand -13.0%0.4%3.9 $2.71 8/15/202319,200 shares $54.53 thousand +12.9%0.5%4 $2.84 7/31/202317,000 shares $49.30 thousand +54.6%0.4%3.7 $2.90 7/15/202311,000 shares $31.13 thousand +15.8%0.3%2.3 $2.83 6/30/20239,500 shares $26.51 thousand -41.7%0.2%2.2 $2.79 6/15/202316,300 shares $47.11 thousand +6.5%0.4%2.3 $2.89 5/31/202315,300 shares $44.52 thousand +1.3%0.4%0.9 $2.91 5/15/202315,100 shares $43.79 thousand +0.7%0.4%0.9 $2.90 4/30/202315,000 shares $42.00 thousand -35.3%0.4%0.7 $2.80 4/15/202323,200 shares $66.82 thousand -27.3%0.6%1 $2.88 3/31/202331,900 shares $88.68 thousand +423.0%0.8%1.1 $2.78 3/15/20236,100 shares $15.92 thousand -14.1%0.2%0.2 $2.61 2/28/20237,100 shares $22.79 thousand +6.0%0.2%0.4 $3.21 2/15/20236,700 shares $20.17 thousand -22.1%0.2%0.4 $3.01 1/31/20238,600 shares $33.63 thousand -34.4%0.2%0.5 $3.91 1/15/202313,100 shares $54.37 thousand +10.1%0.3%1 $4.15 12/30/202211,900 shares $41.44 thousand -90.5%N/A1.1 $3.48 12/15/2022125,500 shares $40.17 thousand -3.9%N/A2.2 $0.32 11/30/2022130,600 shares $47.33 thousand -15.3%N/A1.5 $0.36 11/15/2022154,100 shares $61.64 thousand -33.1%N/A1.6 $0.40 10/31/2022230,200 shares $90.45 thousand -6.9%N/A2.3 $0.39 10/15/2022247,200 shares $113.69 thousand -2.4%N/A2.3 $0.46 9/30/2022253,200 shares $111.43 thousand -4.3%N/A2.3 $0.44 9/15/2022264,700 shares $153.47 thousand +22.5%N/A2.3 $0.58 8/31/2022216,100 shares $121.04 thousand +27.5%N/A2.5 $0.56 8/15/2022169,500 shares $105.12 thousand -34.9%N/A2.3 $0.62 7/31/2022260,300 shares $156.96 thousand +0.4%N/A3.5 $0.60 7/15/2022259,300 shares $163.36 thousand +9.7%N/A2.8 $0.63 6/30/2022236,400 shares $144.44 thousand +36.5%N/A2.8 $0.61 6/15/2022173,200 shares $107.42 thousand -30.2%N/A2 $0.62 5/31/2022248,000 shares $166.16 thousand -13.9%N/A2.8 $0.67 5/15/2022287,900 shares $190.76 thousand -25.4%N/A2.7 $0.66 4/30/2022385,700 shares $284.30 thousand +63.5%N/A2.9 $0.74 4/15/2022235,900 shares $184.00 thousand -7.6%N/A1.8 $0.78 3/31/2022255,200 shares $211.56 thousand +13.8%N/A0.1 $0.83 3/15/2022224,200 shares $159.74 thousand -37.9%N/A0.1 $0.71 2/28/2022360,800 shares $306.68 thousand -22.9%N/A0.2 $0.85 2/15/2022467,900 shares $427.66 thousand -24.4%N/A0.2 $0.91 1/31/2022619,200 shares $582.23 thousand -44.7%N/A0.3 $0.94 1/15/20221,120,000 shares $909.22 thousand +231.1%N/A0.4 $0.81 12/31/2021338,300 shares $243.58 thousand -16.6%N/A0.1 $0.72 12/15/2021405,600 shares $349.63 thousand -32.1%N/A1 $0.86 11/30/2021597,000 shares $579.09 thousand -2.4%N/A1.3 $0.97 11/15/2021611,900 shares $712.50 thousand -25.9%N/A1.3 $1.16 10/29/2021826,100 shares $1.01 million +19.1%N/A1.6 $1.22The End of Elon Musk…? (Ad)The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.Click here to see why the "End of Elon" crowd is about to be wrong again. 10/15/2021693,500 shares $908.49 thousand -6.4%N/A0.5 $1.31 9/30/2021740,700 shares $940.69 thousand -13.0%N/A0.4 $1.27 9/15/2021851,600 shares $1.10 million +1.1%N/A0.1 $1.29 8/31/2021842,100 shares $1.15 million -11.4%N/A0.1 $1.36 8/13/2021950,600 shares $1.28 million -8.6%N/A0.1 $1.35 7/30/20211,040,000 shares $1.34 million -9.6%N/A0.2 $1.29 7/15/20211,150,000 shares $1.73 million +108.0%N/A0.2 $1.50 6/30/2021552,800 shares $718.64 thousand -13.4%N/A0.1 $1.30 6/15/2021638,400 shares $874.61 thousand +9.6%N/A0.4 $1.37 5/28/2021582,300 shares $780.28 thousand -9.3%N/A0.4 $1.34 5/14/2021642,200 shares $732.11 thousand -28.3%N/A0.4 $1.14 4/30/2021895,500 shares $1.33 million +304.1%N/A0.5 $1.49 4/15/2021221,600 shares $292.51 thousand +31.0%N/A0.1 $1.32 3/31/2021169,200 shares $240.26 thousand +18.0%N/A0.3 $1.42 3/15/2021143,400 shares $246.65 thousand +412.1%N/A0.2 $1.72 2/26/202128,000 shares $47.32 thousand -71.6%N/A0 $1.69 2/12/202198,700 shares $203.32 thousand +961.3%N/A0.1 $2.06 1/29/20219,300 shares $15.72 thousand -90.6%N/A0 $1.69 1/15/202199,200 shares $174.59 thousand +91.1%N/A0 $1.76 12/31/202051,900 shares $72.66 thousand -10.1%N/A0 $1.40 12/15/202057,700 shares $86.55 thousand -84.0%N/A0 $1.50 11/30/2020360,800 shares $559.24 thousand +574.4%N/A0.2 $1.55 11/15/202053,500 shares $61.53 thousand +29.5%N/A0 $1.15 10/30/202041,300 shares $56.99 thousand +1,232.3%N/A0.4 $1.38 10/15/20203,100 shares $6.29 thousand -40.4%N/A0 $2.03 9/30/20205,200 shares $10.50 thousand -82.7%N/A0 $2.02 9/15/202030,000 shares $62.10 thousand -86.2%N/A0 $2.07 ATHE Short Interest - Frequently Asked Questions What is Alterity Therapeutics' current short interest? Short interest is the volume of Alterity Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 15th, traders have sold 155,100 shares of ATHE short. 1.06% of Alterity Therapeutics' shares are currently sold short. Learn More on Alterity Therapeutics' current short interest. What is a good short interest ratio for Alterity Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ATHE shares currently have a short interest ratio of 2.0. Learn More on Alterity Therapeutics's short interest ratio. What is a good short interest percentage for Alterity Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.06% of Alterity Therapeutics' floating shares are currently sold short. Is Alterity Therapeutics' short interest increasing or decreasing? Alterity Therapeutics saw a increase in short interest in July. As of July 15th, there was short interest totaling 155,100 shares, an increase of 20.3% from the previous total of 128,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Alterity Therapeutics' float size? Alterity Therapeutics currently has issued a total of 8,870,000 shares. Some of Alterity Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Alterity Therapeutics currently has a public float of 14,630,000 shares. How does Alterity Therapeutics' short interest compare to its competitors? 1.06% of Alterity Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Alterity Therapeutics: DiaMedica Therapeutics, Inc. (5.62%), Cardiff Oncology, Inc. (28.41%), Rapt Therapeutics (5.67%), Lyell Immunopharma, Inc. (3.59%), Aclaris Therapeutics, Inc. (7.19%), SELLAS Life Sciences Group, Inc. (27.80%), Cellectis S.A. (0.47%), Voyager Therapeutics, Inc. (5.66%), Journey Medical Corporation (12.54%), Lifevantage Corporation (22.21%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Alterity Therapeutics stock? Short selling ATHE is an investing strategy that aims to generate trading profit from Alterity Therapeutics as its price is falling. ATHE shares are trading up $0.15 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Alterity Therapeutics? A short squeeze for Alterity Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ATHE, which in turn drives the price of the stock up even further. How often is Alterity Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATHE, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies DiaMedica Therapeutics Short Interest Data Cardiff Oncology Short Interest Data Rapt Therapeutics Short Interest Data Lyell Immunopharma Short Interest Data Aclaris Therapeutics Short Interest Data SELLAS Life Sciences Group Short Interest Data Cellectis Short Interest Data Voyager Therapeutics Short Interest Data Journey Medical Short Interest Data Lifevantage Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ATHE) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
